USEUROPEAFRICAASIA 中文双语Français
Opinion
Home / Opinion / Hot Words

抗癌药准入谈判(kàngáiyào zhǔnrù tánpàn) : Anti-cancer drug medical insurance access negotiations

China Daily | Updated: 2018-08-08 07:00

Pharmacists work at a hospital in Enshi, Central China's Hubei province. The prices of cancer treatment drugs in China are expected to be reduced. [Photo/VCG]

Pharmacists work at a hospital in Enshi, Central China's Hubei province. [Photo/VCG]

According to the State Medical Security Administration, the latest round of negotiations for anticancer drugs to be incorporated into the medical insurance medicine catalog is expected to be completed before the end of September.

The negotiations between the medical insurance institutions and the representatives of the relevant pharmaceutical enterprises will finally determine the payment standards for the relevant drugs.

Centralized drug procurement can effectively promote the reform of public hospitals, reduce the high price of drugs and the cost burden of cancer treatments for patents and their families.

The person in charge of the National Medical Insurance Bureau said that the drugs proposed by the experts are all drugs with high clinical value, high innovation and high patient benefit and they include various types of anticancer drugs targeting renal cell carcinoma, melanoma, chronic granulocytic leukemia and lymph cancer.

The State Medical Security Administration said it has determined the anticancer drugs of this medical insurance access negotiation after an experts' review, selection and voting.

China has taken multiple measures to reduce the economic burden of the patients, especially those with serious diseases such as cancer. Since May 1, China has cut the tariffs on all the imported anticancer drugs to zero.

  
Most Viewed in 24 Hours
China stories
Top
BACK TO THE TOP
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US